Jcovden
E854995
Jcovden is the brand name of Johnson & Johnson’s single-dose COVID-19 vaccine based on an adenovirus vector platform.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine
ⓘ
pharmaceutical product ⓘ vaccine ⓘ |
| administeredAs | 0.5 mL intramuscular dose ⓘ |
| authorizationType |
Emergency Use Authorization in the United States
ⓘ
conditional marketing authorization in the European Union ⓘ |
| belongsToCompany | Johnson & Johnson NERFINISHED ⓘ |
| belongsToTherapeuticArea |
infectious disease
ⓘ
vaccinology ⓘ |
| brandNameOf | Ad26.COV2.S NERFINISHED ⓘ |
| containsGeneticMaterialFor | SARS-CoV-2 spike glycoprotein ⓘ |
| developedBy |
Janssen Pharmaceuticals
NERFINISHED
ⓘ
Janssen Vaccines NERFINISHED ⓘ Johnson & Johnson NERFINISHED ⓘ |
| developedDuring | COVID-19 pandemic ⓘ |
| doseRegimen | single-dose primary vaccination ⓘ |
| hasActiveSubstance | recombinant, replication-incompetent human adenovirus type 26 vector encoding the SARS-CoV-2 spike protein ⓘ |
| hasAdverseEffects |
fatigue
ⓘ
fever ⓘ headache ⓘ injection site pain ⓘ myalgia ⓘ |
| hasAlternativeName |
Ad26.COV2.S
NERFINISHED
ⓘ
Johnson & Johnson COVID-19 Vaccine NERFINISHED ⓘ |
| hasATCCode | J07BX03 ⓘ |
| hasCommonName | Janssen COVID-19 Vaccine NERFINISHED ⓘ |
| hasManufacturer |
Janssen Pharmaceuticals
NERFINISHED
ⓘ
Johnson & Johnson NERFINISHED ⓘ |
| hasRegulatoryStatus |
received Emergency Use Authorization from the U.S. Food and Drug Administration
ⓘ
received conditional marketing authorization from the European Medicines Agency ⓘ |
| hasSeriousAdverseEffects |
Guillain–Barré syndrome
NERFINISHED
ⓘ
anaphylaxis ⓘ thrombosis with thrombocytopenia syndrome ⓘ |
| indicatedFor | prevention of COVID-19 ⓘ |
| indicatedPopulation | adults ⓘ |
| injectionSite | deltoid muscle of the upper arm ⓘ |
| ismRNA | false ⓘ |
| isPartOf | global COVID-19 vaccination campaigns ⓘ |
| isSingleDose | true ⓘ |
| pharmaceuticalForm | suspension for injection ⓘ |
| regulatoryLabelIncludesWarningFor |
Guillain–Barré syndrome
NERFINISHED
ⓘ
thrombosis with thrombocytopenia syndrome ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| storageTemperature | refrigerated conditions (2–8 °C) ⓘ |
| targetsDisease | COVID-19 NERFINISHED ⓘ |
| targetsVirus | SARS-CoV-2 NERFINISHED ⓘ |
| vaccinePlatform |
adenoviral vector vaccine
ⓘ
viral vector vaccine ⓘ |
| vectorType | human adenovirus serotype 26 NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.